",n.parentNode.insertBefore(a,n)};if(!!document.cookie.match(/cookieConsent=true/))window.gaf(); ',{'forceSSL':true});
news
(2 March 2021) Kalos prepares to list in Frankfurt via reverse merger or traditional IPO.
ValiRx PLC Agreement with Kalos Therapeutics:
(10 November 2020) ValiRx (AIM: VAL) a clinical stage drug development company, announces today that it has entered into an agreement with Kalos Therapeutics (Kalos), a US-based private biotechnology company, to evaluate its peptide KTH222 as a drug candidate for treating patients with ovarian cancer.
This website makes use of cookies. Please see our privacy policy for details.